A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.
Regeneron (REGN) announced that the FDA has approved Eylea HD Injection 8 mg for the treatment of patients with macular edema following retinal ...
No changes in protocol recommended for LUGANO and LUCIA clinical trials –– Masked safety data continues to show no safety signals, consistent ...
The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...
Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for ...
Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback